Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices
(eBook)
Description
High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered, and questions explored within the work include: - Fiscal consequences of curing hepatitis C - mRNA vaccines and the race for a cure - Why the government does not deserve a piece of Biopharma's profits - Paying for drugs whose ultimate value is unknown - The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry.
More Details
Notes
Reviews from GoodReads
Citations
Lamattina, J. L. (2022). Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley.
Chicago / Turabian - Author Date Citation (style guide)Lamattina, John L.. 2022. Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley.
Chicago / Turabian - Humanities Citation (style guide)Lamattina, John L., Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley, 2022.
MLA Citation (style guide)Lamattina, John L.. Pharma and Profits: Balancing Innovation, Medicine, and Drug Prices. Wiley, 2022.
Staff View
Hoopla Extract Information
hooplaId | 15161483 |
---|---|
title | Pharma and Profits |
language | ENGLISH |
kind | EBOOK |
series | |
season | |
publisher | Wiley |
price | 0.99 |
active | 1 |
pa | |
profanity | |
children | |
demo | |
duration | |
rating | |
abridged | |
fiction | |
purchaseModel | INSTANT |
dateLastUpdated | May 06, 2025 06:43:57 PM |
Record Information
Last File Modification Time | Jun 03, 2025 10:37:08 PM |
---|---|
Last Grouped Work Modification Time | Jun 03, 2025 10:22:36 PM |
MARC Record
LEADER | 02876nam a22004575i 4500 | ||
---|---|---|---|
001 | MWT18107126 | ||
003 | MWT | ||
005 | 20250505041750.0 | ||
006 | m o d | ||
007 | cr cn||||||||| | ||
008 | 250505s2022 xxu eo 000 0 eng d | ||
020 | |a 9781119881353 |q (electronic bk.) | ||
020 | |a 1119881358 |q (electronic bk.) | ||
028 | 4 | 2 | |a MWT18107126 |
029 | |a https://d2snwnmzyr8jue.cloudfront.net/jws_9781119881353_180.jpeg | ||
037 | |a 18107126 |b Midwest Tape, LLC |n http://www.midwesttapes.com | ||
040 | |a Midwest |e rda | ||
099 | |a eBook hoopla | ||
100 | 1 | |a Lamattina, John L., |e author. | |
245 | 1 | 0 | |a Pharma and Profits : |b Balancing Innovation, Medicine, and Drug Prices |h [electronic resource] / |c John L. Lamattina. |
264 | 1 | |a [United States] : |b Wiley, |c 2022. | |
264 | 2 | |b Made available through hoopla | |
300 | |a 1 online resource | ||
336 | |a text |b txt |2 rdacontent | ||
337 | |a computer |b c |2 rdamedia | ||
338 | |a online resource |b cr |2 rdacarrier | ||
347 | |a text file |2 rda | ||
506 | |a Instant title available through hoopla. | ||
520 | |a High-level commentary on various facets of the pharmaceutical industry from a key leader in the field This book clearly explains the value that the pharmaceutical industry offers to society which is often underreported against the more negative topic of high drug prices. It also offers an overview for drug discovery and development professionals, highlighting the challenges that such drug hunters should be aware of when developing new drugs. Case studies to illustrate topics like hepatitis C, mRNA vaccines, insulin, and price controls are included to aid in seamless reader comprehension. Written by John LaMattina, former president of Pfizer Global Research and Development and well-known speaker and writer for the pharma industry, sample topics covered, and questions explored within the work include: - Fiscal consequences of curing hepatitis C - mRNA vaccines and the race for a cure - Why the government does not deserve a piece of Biopharma's profits - Paying for drugs whose ultimate value is unknown - The impact of reduced revenues on R&D This book is a must-read for biopharmaceutical professionals and executives who wish to gain high-level insight into key challenges that must be first understood, then overcome, within the pharmaceutical industry. | ||
538 | |a Mode of access: World Wide Web. | ||
650 | 0 | |a Business. | |
650 | 0 | |a Chemistry. | |
650 | 0 | |a Industries. | |
650 | 0 | |a Medicine. | |
650 | 0 | |a Pharmaceutical biotechnology. | |
650 | 0 | |a Pharmacology. | |
650 | 0 | |a Science. | |
650 | 0 | |a Electronic books. | |
710 | 2 | |a hoopla digital. | |
856 | 4 | 0 | |u https://www.hoopladigital.com/title/15161483?utm_source=MARC&Lid=hh4435 |z Instantly available on hoopla. |
856 | 4 | 2 | |z Cover image |u https://d2snwnmzyr8jue.cloudfront.net/jws_9781119881353_180.jpeg |